Copy Link Print Information

Frovocimab

(別名: LY 3015014)
カスタマーレビュー

Based on 1 Customer Validation

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 96.78%
  • CAS 番号: 1643672-70-1
  • 分子量:146.38 kDa
  • 保管条件:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Experimental Validation Results for Frovocimab
  • Experimental Validation Results for Frovocimab
  • Experimental Validation Results for Frovocimab
  • Frovocimab Chemical Structure
    Frovocimab 構造式
CAS 番号: 1643672-70-1
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Frovocimab おすすめ製品:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products
Keywords
MOQ
Minimum order quantity
100 mg

お問い合わせ 在庫あり

Other size
お問い合わせ
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 1/16

    Human IgG4 kappa

  • 1/16

    Immobilized PCSK9 Protein, Human (HEK293, C-His, HY-P70545A) can bind Frovocimab. The EC50 for this effect is 2.837 ng/mL.

  • 1/16

    Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Frovocimab (anti-PCSK9) (HY-P99626). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

  • Frovocimab Chemical Structure
    1/16
  • Frovocimab
  • Immobilized PCSK9 Protein, Human (HEK293, C-His, HY-P70545A) can bind Frovocimab. The EC50 for this effect is 2.837 ng/mL.
  • Flow Cytometry analysis of Hela cells labelling PCSK9 (red) with Frovocimab (anti-PCSK9) (HY-P99626). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).